...
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
【24h】

Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.

机译:在过继性T细胞抗肿瘤免疫疗法中,将CD8 + T效应子建模为记忆过渡。

获取原文
获取原文并翻译 | 示例

摘要

Adoptive T-cell therapy with CD8(+) CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8(+) T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8(+) T cells from short-term CTLs in vitro and upon transfer in vivo, including their antitumor activity. Ovalbumin (OVA)-specific OT-I CTLs acquired phenotypic and functional properties of memory cells 2 to 3 days later either by lowering the concentration of antigen to a level that does not support primary responses and providing a survival signal through transgenic Bcl-2 in vitro or simply by transferring early day 3 CTLs to antigen-free lymphoid-replete mice. In lymphoid-replete mice, established OVA-expressing E.G7 tumor was rejected by short-term CTLs that simultaneously acquired memory-like properties in secondary lymphoid tissues, where tumor antigen level remained low. Collectively, these data indicate that CTLs readily converted to memory-like cells upon lowering antigen to a concentration that selectively supports memory responses and suggest that such conversion predicts successful adoptive immunotherapy.
机译:CD8(+)CTL的过继性T细胞疗法通常以转移的T细胞持久性差和效应反应有限为特征。当抗原激活的CD8(+)T细胞表达记忆细胞的特性时,已经注意到改善的持久性和治疗功效。进行当前的研究是为了更精确地表征短期CTL在体外和体内转移后,包括其抗肿瘤活性的记忆样CD8(+)T细胞的发展。卵清蛋白(OVA)特异性OT-1 CTL在2至3天后通过降低抗原浓度至不支持主要应答的水平并通过转基因Bcl-2提供存活信号来获得记忆细胞的表型和功能特性体外或简单地将第3天的CTL转移至无抗原的淋巴样充足的小鼠中。在充满淋巴的小鼠中,已建立的表达OVA的E.G7肿瘤被短期CTL排斥,该CTL同时在次级淋巴组织中获得记忆样特性,而肿瘤抗原水平仍然很低。总体而言,这些数据表明,在将抗原降低至选择性支持记忆反应的浓度后,CTL容易转化为记忆样细胞,并表明这种转化预示着成功的过继免疫疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号